A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this clinical research study is to discover if the study drug Famitinib
Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.